Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double attack on blood disorder: could two drugs beat one for stubborn ITP?

NCT ID NCT07687134

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding telitacicept to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that hasn't improved with steroids. ITP is a bleeding disorder where the immune system destroys platelets. The study aims to see if the combination helps more patients maintain safe platelet levels without bleeding for 24 weeks after stopping treatment. Forty participants will be randomly assigned to either the combination or eltrombopag alone for 12 weeks, then followed for another 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
eltrombopag and telitacicept
What this could lead to
If successful, this combination could offer a more durable remission for people with immune thrombocytopenia who do not respond to steroids.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply broadly. The combination may not improve outcomes and could increase side effects like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.